A Novel Prognostic Model of De Novo Metastatic Hormone-Sensitive Prostate Cancer to Optimize Treatment Intensity

1092 Japanese patients diagnosed with de novo metastatic hormone-sensitive prostate cancer between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens were assigned to the discovery or validation cohorts.